Smoking Cessation as Effective as 3 Meds in Secondary CVD Prevention: 5 Event-free Years
Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.
Should Medicare Cover Medical Marijuana: Medicare Recipients Respond
Medical cannabis is already popular with Medicare recipients and many fear insurance coverage will drive up the cost. Find out what else a new survey found.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 12, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
CDC: STDs Continued to Rise during Pandemic, Likely to Keep Increasing in 2021
Cases of gonorrhea, syphilis, and congenital syphilis in 2020 surpassed 2019 levels in the US, according to the CDC's 2020 STD Surveillance Report.
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
US patients diagnosed with migraine: 40 million. US headache specialists: 600. Primary care is the answer, according to Christopher Gottschalk, MD.
FDA Clears Fitbit Algorithm to Detect Atrial Fibrillation
The FDA clearance for the FitBit algorithm will provide another widely tested tool for patient and clinicians to help identify arrhythmias earlier and avoid severe cardiocerebrovascular events.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 11, 2022
CGRP Inhibition for Migraine: Side Effects are Few but Pay Attention for These
The CGRP inhibitor class of injectable migraine preventive agents has a very favorable side effect profile but the drugs do come with some cautions, says Christopher Gottschalk, MD.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 8, 2022
Antihypertensive Treatment during Pregnancy Linked to Better Outcomes, According to New NIH Study
ACC 2022: Use of antihypertensive therapy in pregnant women was associated with better pregnancy outcomes, such as preeclampsia and fetal or neonatal death.
Finerenone Consistently Reduced Cardiorenal Risk Regardless of ASCVD History in FIDELITY
In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.
New Diabetes Device Comparison Platform Supports Clinical Decision-making, Prescribing
DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.
Rimegepant for Acute Migraine May Reduce Use of, Reliance on Opioids: New Data
Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 7, 2022
Diabetes Technology Myths & Facts for Primary Care Practitioners
Initiating diabetes technology of any kind is a big step for patients, but also for a lot of primary care clinicians. If you have concerns, these myths and facts are for you.
ACC, AHA, HFSA 2022 Heart Failure Management Guidelines: A Guideline Topline
The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.
Patient Education via Mobile Apps: 5 Clinical Considerations
To recommend, or not recommend: that is the question clinicians may ponder when considering education-focused apps for patients. Here, 5 points to help decide.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 5, 2022
Sotagliflozin Reduced MACE Risk in Patients With and Without Prior CVD, in New Analysis of SCORED Clinical Trial
ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.
FDA Grants Priority Review to Dupilumab sBLA for Eosinophilic Esophagitis
Dupilumab is the only biologic to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.
